Stock Research: Supernus Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Supernus Pharma

NasdaqGM:SUPN US8684591089
51
  • Value
    100
  • Growth
    55
  • Safety
    Safety
    27
  • Combined
    45
  • Sentiment
    49
  • 360° View
    360° View
    51
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. It operates in the biopharmaceutical industry with products like Qelbree, GOCOVRI, and Oxtellar XR. The company focuses on the treatment of CNS diseases. In the last fiscal year, the company had a market cap of $1,885 million, profits of $593 million, and revenue of $662 million, with 674 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 51 (better than 51% compared with alternatives), overall professional sentiment and financial characteristics for the stock Supernus Pharma are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Supernus Pharma. The consolidated Growth Rank has a good rank of 55, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 55% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 100 which means that the company has a financing structure that is safer than 100% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 27 which means that the share price of Supernus Pharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 73% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 49, which means that professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. ...read more

more
Index
Moonshot Tech
NASDAQ
D.J. US Pharmaceutical
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 18 29 37
Growth
55 51 49 77
Safety
Safety
100 100 75 96
Sentiment
49 66 32 80
360° View
360° View
51 73 32 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
26 23 48 57
Opinions Change
50 68 50 96
Pro Holdings
n/a 92 45 22
Market Pulse
69 43 33 56
Sentiment
49 66 32 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 18 29 37
Growth
55 51 49 77
Safety Safety
100 100 75 96
Combined
45 63 52 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
45 40 50 71
Price vs. Earnings (P/E)
43 32 37 64
Price vs. Book (P/B)
50 39 44 1
Dividend Yield
1 1 1 1
Value
27 18 29 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
80 10 43 51
Profit Growth
20 57 91 23
Capital Growth
25 48 29 97
Stock Returns
71 83 41 79
Growth
55 51 49 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 53 62
Refinancing
53 56 43 53
Liquidity
81 82 84 84
Safety Safety
100 100 75 96

Similar Stocks

Discover high‑ranked alternatives to Supernus Pharma and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.